Connect with us

Technology

3D Printing Medical Devices Market size is set to grow by USD 7.07 billion from 2024-2028, Increased demand for personalized or customized medical devices boost the market, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global 3D printing medical devices market size is estimated to grow by USD 7.07 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 25.2%  during the forecast period. Increased demand for personalized or customized medical devices is driving market growth, with a trend towards rising focus on the research for the use of 3D printing process to manufacture living organs and cell structures. However, high initial setup cost of 3d printing facility  poses a challenge. Key market players include 3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

3D Printing Medical Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 25.2%

Market growth 2024-2028

USD 7079.6 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

19.78

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Germany, UK, Japan, and China

Key companies profiled

3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd.

Market Driver

The 3D printing of medical devices, specifically in the field of bioprinting, represents a significant advancement in healthcare technology. This process involves the precise layering of cells, biologic scaffolds, and growth factors to create bioidentical tissue, such as stem cells, skin grafts, and bone and cartilage. Unlike traditional 3D printers that use plastic or metals as raw materials, 3D bioprinters utilize a computer-guided pipette to layer living cells, referred to as bioink, to create artificial living tissues. One of the most promising applications of 3D bioprinting is in organ replacement. This technology holds the potential to address the organ donor shortage and reduce rejections by creating organs that better meet the requirements of the body. For instance, 3D printed bone features a micropore surface that allows osteocytes to adhere, join, and heal better than traditional metal implants. ORGANOVO, a biotechnology company, is pioneering the use of 3D bioprinting to develop in vivo liver tissues for treating rare, life-threatening diseases. Their product, the ExVive 3D Bioprinted Human Liver Tissues, can be used for drug exposure and metabolism studies, offering a valuable alternative to organ transplantation. Allevi and SHIBUYA are among the companies leading the way in 3D bioprinting technology. Allevi introduced the first desktop 3D bioprinter capable of printing living tissues using human cells, while SHIBUYA’s 3D bioprinter is the first cell culture system for building complex cell-based structures. The potential of 3D bioprinting is driving increased R&D efforts in developing devices for this technology. As technological advances continue, 3D printing medical devices are expected to see widespread adoption, fueling the growth of the global 3D printing medical devices market. 

The 3D Printing Medical Devices market is experiencing significant growth due to its ability to produce customized, patient-specific solutions for various medical applications. Stereolithography (SLA) and digital light processing are popular 3D printing technologies used in creating prosthetics implants, orthopedic implants, and wearable medical devices. Dentistry and orthodontics also benefit from 3D printing, with applications including dentures, bone scaffolds, and hearing aids. Tissue-engineered products, remote patient monitoring, telemedicine, and vital signs monitoring are other areas where 3D printing is making an impact. Complex medical procedures, such as implantable and non-implantable medical devices, drug testing, and organ and tissue production, are also being revolutionized by this technology. Computer-aided manufacturing and design, diagnostic centers, medical institutions, and 3D printing laboratories are embracing 3D printing to provide personalized solutions. Laser beam technology, minimally invasive surgery, and surgical equipment are other areas where 3D printing is making a difference. Patient CAD images are used to create patient-specific models and customized implants, including cranial implants for neurosurgery and human skull repairs. Overall, 3D printing is transforming the medical industry by enabling the production of customized, high-quality medical devices in a layer-wise manner. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

The 3D printing medical devices market faces significant challenges due to high capital costs. Equipment for 3D printing or outsourced print service contracts, advanced software for post-processing, and proprietary raw materials contribute to these costs. Desktop FDM or SLA machines cost less than USD5,000, but high-end additive manufacturing printers range from USD200,000 to USD850,000 or even millions. Skilled personnel and training are also necessary, adding to the expenses. A clinical 3D printing lab requires ancillary staff for printing. Production time, ranging from hours to days, limits its use in mass manufacturing. These factors hinder the widespread adoption of 3D printers, potentially impacting the growth of the market negatively.The 3D printing medical devices market is experiencing significant growth due to the advantages it offers in creating customized solutions for various medical needs. However, there are challenges that need to be addressed. For physicians, the use of 3D-printed medical devices in elective surgical procedures requires careful consideration for complex prosthetic limbs and brain designs. Surgeons prefer titanium alloys for surgical tools, but cancer patients benefit from biocompatible materials as drug contact materials. Hearing aid manufacturers are exploring 3D-printed hearing aid devices using biocompatible materials for personalized solutions. CAD/CAM technology and desktop printers are revolutionizing dental clinics and hospitals, providing dental restoration, surgical planning, and personalized prosthetics. Orthopedic prosthetics and surgical instruments also benefit from 3D printing, improving surgical outcomes, operation time, and reducing post-surgical complications. Mechanical protection for tissues and organs is a promising area for 3D printing, with potential applications in organ transplantation and living cells using biomaterials. However, biosafety concerns and ethical issues surrounding the use of human cells and tissues need to be addressed by regulatory bodies like the Human Tissue Authority. Photopolymerization and Medical device manufacturers are using rapid prototyping to innovate, while healthcare professionals embrace the technology for prosthetics, surgical instruments, personalized prosthetics, orthotics, surgeon comfort, and fatigue prevention.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This 3d printing medical devices market report extensively covers market segmentation by  

Application 1.1 Orthopedic and spinal1.2 Dental1.3 Hearing aids1.4 OthersEnd-user 2.1 Hospitals and clinics2.2 Academic institutes2.3 Pharma and biotech companies2.4 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Orthopedic and spinal-  The 3D printing medical devices market encompasses the production of orthopedic and spinal implants using 3D printing technology. This technology enables the fabrication of standard-sized implants, patient-matched implants, and custom implants for individuals with deformities. Hospitals and ambulatory surgery centers are major end-users, as 3D printing allows for the creation of complex structures and individualized implants. Orthopedic and spinal applications dominate the market due to the rising prevalence of related disorders, increasing demand for personalized implants, and the need for advanced surfaces and structures. The technology’s ability to manufacture lattice structures and porous surfaces promotes bone ingrowth and improves implant stability. Titanium implants, commonly used in orthopedics, benefit from 3D printing’s ability to create greater porosity, enhancing bony ingrowth and improving implant stability. In the field of prosthetics, 3D printing significantly reduces manufacturing time and costs while maintaining functionality. The technology’s affordability makes it particularly suitable for children who quickly outgrow their prosthetic limbs. Vendors are increasing investments in R&D to develop advanced orthopedic and spinal implants, further fueling market growth. Key factors driving the market include the aging population, increasing prevalence of orthopedic and spinal disorders, and the demand for customized implants. These factors are expected to propel the growth of the global 3D printing medical devices market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products, including implants, hearing aids, bone scaffolds, surgical equipment, and more. The process begins with the creation of patient CAD images, which are then used to manufacture standard implants or personalized prosthetics, surgical instruments, and orthotics. The benefits of 3D printing in medical devices extend beyond patient comfort, as it also allows for the production of implantable and non-implantable medical devices using biomaterials, as well as drug testing and potential applications in organ transplantation and tissue engineering. Rapid prototyping and computer-aided manufacturing are key technologies driving the growth of this market, with healthcare professionals and medical device manufacturers embracing the technology to improve patient outcomes and surgical procedures.

Market Research Overview

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products such as implants, hearing aids, bone scaffolds, surgical equipment, and more. The use of patient CAD images ensures a perfect fit and optimal surgical outcomes, reducing operation time and post-surgical complications. 3D printing technology is being applied in various medical fields, including neurosurgery, orthopedics, and dentistry. For instance, it is used to create cranial implants, patient-specific models, and surgical tools for complex procedures. The use of biocompatible materials, such as titanium alloys and photopolymers, ensures the safety and effectiveness of 3D-printed medical devices. The market for 3D-printed medical devices is vast and diverse, encompassing elective surgical procedures, complex prosthetic limbs, brain designs, surgical instruments, and more. The technology is also being used in tissue engineering and organ transplantation, with the potential to print living cells and biomaterials. However, the use of 3D printing in medicine raises biosafety concerns and ethical issues, particularly with regard to the Human Tissue Authority and patient privacy. Medical device manufacturers are working to address these challenges through the use of CAD/CAM technology, rapid prototyping, and collaboration with healthcare professionals. The market for 3D-printed medical devices includes hearing aid manufacturers, dental clinics, hospitals, and surgical planning centers. The technology is also being used to create implantable and non-implantable medical devices, wearable medical devices, and diagnostic tools. The potential applications of 3D printing in medicine are vast, from surgical planning and dental restoration to remote patient monitoring and telemedicine. The future of medicine is undoubtedly 3D printed.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationOrthopedic And SpinalDentalHearing AidsOthersEnd-userHospitals And ClinicsAcademic InstitutesPharma And Biotech CompaniesOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/3d-printing-medical-devices-market-size-is-set-to-grow-by-usd-7-07-billion-from-2024-2028–increased-demand-for-personalized-or-customized-medical-devices-boost-the-market-technavio-302209578.html

SOURCE Infiniti Research, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IMCC Launches “DEEP C” Digital Transformation Program to Advance Operational Excellence

Published

on

By

KUWAIT CITY, April 24, 2026 /PRNewswire/ — International Marine Construction Company (IMCC) has announced the launch of its company-wide corporate transformation program, “DEEP C,” during a launch event held on 20 April 2026, bringing together employees from across the organization under the ethos of “Think New, Act New.”

 

 

The “DEEP C” program marks a significant milestone in IMCC’s evolution, reinforcing its commitment to operational excellence, strengthened governance, and sustainable growth through the adoption of integrated digital systems and data-driven practices.

At the core of the initiative is a structured transformation model built around five strategic pillars — Drive, Enable, Execute, Perform, and Connect — designed to ensure alignment between strategy, execution, and measurable business outcomes across all functions.

The program reflects IMCC’s ambition to embed a forward-looking, performance-driven culture across the organization, enabling more efficient operations, improved decision-making, and greater alignment across its business functions.

Speaking at the launch, Maen Razouqi, Vice Chairman and CEO of IMCC, emphasized the strategic importance of the initiative, stating that the program represents a step-change in how the company operates, with a clear focus on accountability, integration, and measurable outcomes. As Chair of the DEEP C Steering Committee, he reaffirmed IMCC’s commitment to driving this transformation across all levels of the marine sectors and its solutions.                                             .          

He further noted that the program reflects what IMCC stands for as a business, placing our customers and people at the center, driving performance with discipline, and delivering sustainable returns, while strengthening its commitment to all stakeholders, from clients to employees.

Khalid Al-Bustan, Vice Chair of the DEEP C Steering Committee and Head of the Program, highlighted the execution approach, noting that the initiative will enable the business through digital tools, standardized processes, and stronger cross-functional alignment to deliver sustainable results.                             .

He added that, in line with the vision of the Board of Directors the “DEEP C” Transformation Program will support the business in achieving more consistent and measurable outcomes, while ensuring that our customers and people remain at the core of how the organization operates.

As part of IMCC’s broader commitment to environmental, social, and governance (ESG) principles, the “DEEP C” program supports the development of more transparent, efficient, and resilient operations across its activities globally. By enhancing governance standards, strengthening operational performance, and investing in people and systems, the initiative contributes to supporting long-term sustainability and reinforcing regional collaboration within the energy and marine sectors.

The program will be rolled out in phases, supported by a structured governance framework and clear performance metrics to ensure effective implementation and long-term value creation.

The launch of “DEEP C” reflects IMCC’s continued focus on innovation and transformation as it strengthens its position as a leading offshore and marine services provider in the region and globally.

About IMCC

International Marine Construction Company (IMCC), established in 1974, is one of Kuwait’s longest-standing offshore and marine service providers supporting the energy, maritime, and infrastructure sectors.

IMCC delivers integrated offshore and marine solutions, including marine construction, subsea services, offshore logistics, vessel operations, and port and terminal support, backed by strong engineering capability and high operational standards.

With over five decades of experience, IMCC has built a strong regional presence across Kuwait and the GCC, supported by strategic partnerships and a commitment to safety, quality, and performance in all operations.

The company continues to invest in modern assets, digital capabilities, and people to support the evolving needs of the energy and marine sectors.

For more information, please visit:
www.1imcc.com
https://www.linkedin.com/company/international-marine-construction-co-imcc/

Photo – https://mma.prnewswire.com/media/2965024/Group_Photo.jpg
Photo – https://mma.prnewswire.com/media/2965025/Maen_Razouqi.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/imcc-launches-deep-c-digital-transformation-program-to-advance-operational-excellence-302752723.html

Continue Reading

Technology

LexisNexis introduces Protégé General AI in Hong Kong, expanding secure, integrated access to general purpose AI for legal professionals

Published

on

By

HONG KONG, April 24, 2026 /PRNewswire/ — LexisNexis® Legal & Professional, a leading global provider of AI‑powered analytics and decision tools, today announced the availability of LexisNexis Protégé™ General AI for customers in Hong Kong. Protégé General AI is available within Lexis+® Hong Kong, expanding the personalised agentic AI capabilities of Protégé to provide secure access to general‑purpose AI within a single platform.

As legal work becomes increasingly AI-powered, Protégé General AI offers a private, encrypted solution that enables legal professionals to conduct a wider range of AI-assisted work without switching tools. With the click of a toggle, users can move seamlessly between Protégé Legal AI and Protégé General AI, allowing them to manage both legal-specific and everyday tasks within a single, secure environment.

Protégé General AI is designed for legal professionals and developed with strong levels of privacy, security, and flexibility. It enables users to conduct general research, explore topics, draft communications intended for both legal and non-legal audiences, and enrich legal work with real-world context, while remaining within the LexisNexis ecosystem ensuring data security and privacy.

General AI responses are supported by web content, and where legal context is relevant, currently grounded through LexisNexis verification capabilities, helping users work with greater confidence across a broader range of tasks.

“Legal professionals in Hong Kong are increasingly looking for ways to use AI across more of their day-to-day work, without compromising privacy or control,” said Michael Sit, Managing Director, Hong Kong and Greater China, LexisNexis. “Protégé General AI brings general-purpose AI and authoritative legal AI together in one secure platform, supporting uninterrupted workflows and more consistent outcomes which is very important for HK based lawyers who are often working across multiple continents and matters.”

By securely integrating Protégé General AI and Protégé Legal AI within Lexis+ Hong Kong, LexisNexis enables legal professionals to choose the appropriate AI experience for each task. Legal-specific work continues to be supported by authoritative LexisNexis legal content, while general-purpose tasks are supported within the same secure platform.

The launch of Protégé General AI in Hong Kong marks an important step in LexisNexis’ continued expansion of its agentic AI platform. Following the April availability, LexisNexis plans to progressively introduce additional Protégé capabilities and enhancements in the second half of the year.

Protégé is developed responsibly with human oversight and is built on the LexisNexis global technology platform, which integrates extractive AI, generative AI, and agentic AI. Customer inputs are not used to train any LLM models, and enterprise-grade security and governance are embedded throughout the platform.

As part of the expanding Protégé experience within Lexis+ Hong Kong, LexisNexis has also introduced Protégé Vault for Hong Kong customers. Vault provides a secure, persistent workspace that allows users to upload, store, and revisit documents over time, supporting analysis, drafting, and comparison tasks grounded in their own firm’s materials.

For more information on LexisNexis Protégé™, visit the official website here.

About LexisNexis Legal & Professional

LexisNexis® Legal & Professional provides AI-powered legal, regulatory, business information, analytics, and workflows that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,900 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

About RELX

RELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 36,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £72.5bn | €87.4bn | $91.6bn

 

View original content:https://www.prnewswire.com/apac/news-releases/lexisnexis-introduces-protege-general-ai-in-hong-kong-expanding-secure-integrated-access-to-general-purpose-ai-for-legal-professionals-302752727.html

SOURCE LexisNexis

Continue Reading

Technology

XRP Healthcare: XRPHAI, a Utility Token Rewarding Healthy Actions, to Go Live on MEXC April 27 at 10:00 AM UTC

Published

on

By

DUBAI, UAE, April 24, 2026 /PRNewswire/ — XRP Ledger-powered utility token driving the XRPH AI ecosystem, with XRPHAI Rewards activating April 28 and enhanced rewards for XRPH holders to follow shortly. See the official MEXC announcement: https://www.mexc.com/announcements/article/17827791535042.

 

 

XRP Healthcare, the first AI healthcare platform built on the XRP Ledger, today confirms that $XRPHAI (the “XRPHAI” utility token) will go live for trading on MEXC at 10:00 AM UTC on April 27, 2026, marking the next phase in the evolution of its unified XRPH AI ecosystem. The XRPH AI Rewards system will activate on April 28, enabling users to begin earning rewards for healthy actions within the XRPH AI App through verified participation.

This marks the first time XRPHAI has been made available for trading, with no prior market activity, private sale, or exchange listing. The initial listing on MEXC provides users with first access to the token as it enters the market.

MEXC has recently undertaken a platform-wide rebrand focused on strengthening its global presence and advancing its position among leading digital asset exchanges. Serving over 40 million users across more than 170 countries, the exchange continues to expand its offering through the introduction of new projects and infrastructure designed to support long-term growth.

XRP Healthcare operates as a connected ecosystem where technology, application, and user engagement work together. XRPH serves as the foundational token layer, while XRPHAI operates as the utility token powering rewards within the XRPH AI App. This structure aligns platform activity with real-world healthcare engagement, ensuring scalability and practical use.

XRPHAI enables a system designed to reward verified healthcare participation within the XRPH AI App. Users can earn XRPHAI through AI-guided health interactions, CalmXRPH wellness sessions, image-based health assessments, educational participation and referrals, as well as through use of the XRPH Prescription Savings Card across more than 68,000 pharmacies in the United States, including Walmart, CVS, and Walgreens. This model introduces a practical approach to digital healthcare, linking real engagement with measurable rewards.

The XRPH AI App and XRPH Wallet are designed to operate seamlessly together, allowing users to earn XRPHAI within the app, transfer rewards directly to the wallet, and hold, manage, or utilise those rewards within the broader ecosystem. This integration connects user participation with underlying infrastructure in a single, unified experience.

Following the initial activation of the rewards system, XRP Healthcare expects to introduce an enhanced rewards layer shortly afterwards. This will enable users holding XRPH in the XRPH Wallet to receive increased XRPHAI rewards, directly linking long-term participation and token holding with greater earning potential across the ecosystem.

Global healthcare represents an estimated $10 trillion market, with digital health continuing to expand rapidly. With over 6.8 billion smartphone users worldwide and growing daily, healthcare delivery is increasingly shifting toward accessible, mobile-first platforms, positioning XRP Healthcare at the intersection of artificial intelligence, mobile technology, and real-world healthcare engagement on a global scale.

XRPHAI will be listed on MEXC at 10:00 AM UTC on April 27, 2026. The XRPH AI Rewards system will go live on April 28, ensuring that market trading and price discovery occur first, followed by reward activation aligned with a live market environment.

XRPHAI has a fixed maximum supply of 1,000,000,000 tokens, with the issuing account permanently disabled (commonly referred to as ‘blackholed’) to prevent any additional minting, reinforcing a transparent and finite token structure. Further details are available in the whitepaper: https://www.xrphealthcare.ai/docs/ai/xrph-ai-white-paper.pdf.

At the core of the system is Proof of Health™, a model designed to reward verified AI-driven healthcare engagement through a structured digital rewards system. Powered by XRPHAI and supported by XRPH infrastructure, this model ensures that participation is measurable, meaningful, and aligned with real-world outcomes.

Following its initial listing, XRP Healthcare intends to pursue additional listings on higher-tier exchanges throughout 2026, supporting broader access, increased liquidity, and continued ecosystem growth.

XRP Healthcare continues to focus on expanding its AI-driven healthcare ecosystem, with ongoing development aimed at increasing user engagement, accessibility, and real-world application.

Kain Roomes, Founder and CEO of XRP Healthcare, said:

“We are building a connected healthcare ecosystem where participation, technology, and real-world use come together. XRPHAI enables us to reward meaningful engagement at scale, while maintaining a strong foundation through XRPH.”

Laban Roomes, Co-Founder and Chief Operating Officer of XRP Healthcare, added:

“This has always been about building one ecosystem. XRPH provides the foundation, and XRPHAI introduces a structured way to reward participation within the XRPH AI App. The integration between the app and the wallet ensures users can move seamlessly across the ecosystem while benefiting from their engagement.”

For more information, visit https://www.xrphealthcare.ai/docs/ai/xrph-ai-white-paper.pdf and https://www.xrphealthcare.ai/xrphai-rewards.

About XRP Healthcare

XRP Healthcare is the first AI healthcare platform built on the XRP Ledger, combining artificial intelligence, digital health infrastructure, and blockchain interoperability to expand global access to healthcare services. Through its XRPH AI platform and healthcare infrastructure strategy, the company is building a scalable model that connects digital engagement with real-world healthcare delivery.

Photo: https://mma.prnewswire.com/media/2965032/XRP_Healthcare_XRPHAI_MEXC.jpg
Logo: https://mma.prnewswire.com/media/2365357/XRP_Healthcare_Logo.jpg

 

 

Media Contact
Sarah James
info@xrphealthcare.com

View original content:https://www.prnewswire.co.uk/news-releases/xrp-healthcare-xrphai-a-utility-token-rewarding-healthy-actions-to-go-live-on-mexc-april-27-at-1000-am-utc-302752733.html

Continue Reading

Trending